Study of Macrophage Function and of the GM-CSF Signaling Pathway in Alveolar Proteinosis by Mutations of the MARS Gene
| Registry | NCT04811274, acronym MacroMARS |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 20 (Actual) |
| Sponsor | Assistance Publique - Hôpitaux de Paris (Other); collaborators: URC-CIC Paris Descartes Necker Cochin |
| Conditions | Pulmonary Alveolar Proteinosis (PAP), MARS, Genetic Mutation |
| Interventions | Blood collection, Bronchoalveolar lavage fluid collection (Biological) |
| Dates | start 2021-06-07, primary completion 2021-11-06, completion 2021-11-06, first posted 2021-03-23, last updated 2026-04-03 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
All trials for Pulmonary Alveolar Proteinosis (PAP) All trials for MARS All trials of Blood collection All trials of Bronchoalveolar lavage fluid collection
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis (PAP), but the pathophysiological mechanisms of the respiratory phenotype are not known.
The main hypothesis is that the PAP phenotype in these patients is secondary to a defective clearance of the surfactant by the alveolar macrophages.
The main objective of the study is to study the clearance capacity of lipoproteinaceous material by macrophages of patients with MARS related PAP. This will be investigate in cultured macrophages derived from peripheral blood monocytes of patients (patients with MARS related PAP) and controls (patients without MARS related PAP).
Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease characterized by the accumulation of lipoproteinaceous material within the pulmonary alveoli, resulting in the majority of cases from a defective clearance of the surfactant by intra-alveolar macrophages.
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis, but the pathophysiological mechanisms leading to mutations in the respiratory phenotype are not known.
The main hypothesis is that the alveolar proteinosis phenotype in these patients is secondary to a defective clearance of the surfactant by the alveolar macrophages.
The main objective of the study is to study the clearance capacity of lipoproteinaceous material by macrophages of patients with MARS related PAP. This will be investigate in cultured macrophages derived from peripheral blood monocytes of patients (patients with MARS related PAP) and controls (patients without MARS related PAP).
The subjects and the controls will be included during a hospitalization during which a blood sample and a bronchoscopy with broncoalveolar lavage must be performed as part of their care.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Patients | Biological: Blood collection; Biological: Bronchoalveolar lavage fluid collection | Minor patients with alveolar proteinosis by mutations of the MARS gene. | |
| Controls | Biological: Blood collection; Biological: Bronchoalveolar lavage fluid collection | Minors patients without alveolar proteinosis. |
Sex: All, ages: any to 17 Years
Inclusion Criteria: * Minors from 0 to 17 years hospitalized for their care at Necker Enfants Malades hospital and for whom a blood sample and a bronchoscopy with bronchoalveolar lavage must be performed as part of their care * Information and consent of the holders of parental authority and the patient Exclusion Criteria: \- Refusal of holders of parental authority or patient
| Facility | City | Country | Status |
|---|---|---|---|
| Hôpital Necker-Enfants Malades | Paris | France |